Hypothesis: Synergistic senolytic‑epigenetic reprogramming via mitochondrial ROS‑FOXO3 signaling

Core idea Intermittent dosing of dasatinib + quercetin (D+Q) lowers mitochondrial reactive oxygen species (ROS) in senescent cells, which activates the transcription factor FOXO3. FOXO3 directly up‑regulates the expression of OCT4, SOX2 and KLF4 (OSK) and enhances chromatin accessibility at pluripotency promoters, thereby priming cells for partial epigenetic reprogramming. Conversely, a brief, inducible pulse of OSK reduces the senescence‑associated secretory phenotype (SASP) by stimulating autophagy‑mediated clearance of damaged mitochondria and lysosomes, making residual senescent cells more vulnerable to senolytic attack. The combined regimen should therefore achieve greater senescent‑cell depletion and functional improvement than either approach alone.

Testable predictions

1. In aged mice, a schedule of D+Q (once weekly for 3 weeks) followed by a 48‑hour doxycycline‑inducible OSK pulse will reduce SA‑β‑gal‑positive cells in liver and muscle by >70 % compared with D+Q or OSK alone (p<0.01).
2. The same combination will lower plasma IL‑6 and CXCL10 (SASP biomarkers) to levels seen in young adult mice, whereas monotherapies achieve only ~30 % reductions.
3. FOXO3 knockout (liver‑specific) will abolish the synergistic decrease in SA‑β‑gal and the increase in OCT4/SOX2/KLF4 mRNA after D+Q treatment, confirming FOXO3 as the mechanistic link.
4. Mitochondrial ROS measured by MitoSOX fluorescence will be significantly lower after D+Q, and rescuing ROS with antimycin A will block FOXO3 nuclear translocation and the subsequent OSK upregulation.

Experimental outline

• Animals: 20‑month‑old C57BL/6J mice, n=10 per group (control, D+Q only, OSK only, D+Q→OSK, OSK→D+Q, FOXO3‑LKO + D+Q→OSK).
• Interventions: D+Q (5 mg/kg dasatinib + 50 mg/kg quercetin, i.p., weekly ×3); inducible OSK (doxycycline 2 mg/ml in drinking water for 48 h).
• Readouts: SA‑β‑gal staining, qPCR for OCT4/SOX2/KLF4, FOXO3 target genes (SOD2, CAT), mitochondrial ROS (MitoSOX flow cytometry), SASP cytokine panel, grip strength, treadmill endurance, and histologic fibrosis.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Falsifiability If the D+Q→OSK sequence does not produce a statistically significant greater reduction in senescent‑cell burden or functional improvement over the best monotherapy, or if FOXO3 loss does not diminish the combination effect, the hypothesis is refuted. Likewise, if mitochondrial ROS scavenging abolishes FOXO3 activation but does not affect senolytic efficacy alone, the proposed ROS‑FOXO3‑OSK axis is not required for synergy.

Relevance This hypothesis integrates the modest but consistent senolytic actions of D+Q/[2][3][5] with the epigenetic reset capacity of OSK/[6][8] through a redox‑sensitive signaling node (FOXO3) that links anti‑apoptotic stress responses to chromatin remodeling. Positive results would justify a combined clinical protocol where low‑dose senolytic priming precedes transient epigenetic reprogramming, potentially lowering the required exposure to each modality and reducing risks such as thrombocytopenia (navitoclax) or teratoma formation.

[1] https://lifespan.io/news/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/ [2] https://www.nad.com/news/a-natural-senolytic-supplement-curbs-heart-aging-in-new-clinical-trial [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12456441/ [4] https://doi.org/10.1038/s41593-019-0372-9 [5] https://doi.org/10.007/s11357-022-00542-2 [6] https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials/ [7] https://www.hubmeded.com/blog/epigenetic-reprogramming [8] https://pmc.ncbi.nlm.nih.gov/articles/PMC12798543/